OneMedRadio spoke with Ray Briscuso, Managing Partner and Producer of AdvaMed 2012, to learn about the can’t miss highlights in conference programming. Briscuso also discussed the history of the conference — how a gathering once geared toward trade association types has grown into one of the most important events in facilitating growth company finance in the sector.
September is Sickle Cell Awareness Month, a time when the medical community will gather with the patient population in the hopes of advancing research in this significant unmet medical need. One company, ADVENTRX Pharmaceuticals [NYSE: ANX], is attempting to engage the investor community and the sector’s most promising drug developers through the First Annual Sickle Cell Disease Therapeutics Conference, taking place September 19th, 2012 in New York City.
IMMUNE Pharmaceuticals is an Israeli and US based emerging leader in the development of antibody therapeutics in cancer and inflammation. IMMUNE has multiple drug candidates based on proprietary cytotoxic formulations, linkers and monoclonal antibodies.
How can one optimally design a clinical trial program for a medical device for a FDA clearance/approval submission? OneMedRadio spoke with Dr. Vladimir Dragalin and Dr. Michael Feldstein of Aptiv Solutions to discuss the changing tides of medical device regulatory and the advantages of using an adaptive design trial.
BiognoSYS, a Swiss leader and founder of proteomics in the Greater Zurich Area, is developing targeted proteomics based on a novel mass spectrometric technology.
The Securities and Exchange Commission missed a deadline of July 4, 2012 to adopt rules lifting a general advertising ban for private securities offerings as a part of the JOBs Act.
Delenex Therapeutics, a Swiss biotech in the Greater Zurich Area is developing antibodies to treat serious medical conditions with high unmet need.
As an anchor sponsor for OneMedForum NY 2012, The Greater Zurich Area AG will be hosting a workshop Thursday morning on “Entering Europe.”
Marco Estermann, Head Issuer Relations of SIX Swiss Exchange in the Greater Zurich Area sat down with OneMedRadio to discuss the growth of the Swiss biotech sector and particularly different strategies this sector employs to raise capital.
Napodano, a senior biotech analyst for Zacks Investment Research discusses 4 regenerative medicine companies making headway in the space.
Copyright © 2024 | WordPress Theme by MH Themes